Numinus wellness inc

Search Search for:. CAN US. Book A call

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies.

Numinus wellness inc

Numinus Wellness Inc. The capital raise is another important step for the mental health care company, which focuses on developing psychedelic-assisted therapies. The financing round also saw contributions from venture fund Integrated V. We see Numinus as playing a critical role in ensuring that therapists have the option to volunteer for experiential training to become fully trained on the latest medicines and their therapeutic methodologies. Scheduled to close around Feb. According to the Numinus, the proceeds from the offering are intended for working capital and general corporate purposes. Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. Post Comment. Sign up. The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry.

What Are Psychedelics? Numinus Wellness Inc.

.

Launched the Numinus Certification Pathway to train and certify psychedelic therapy practitioners, with over unique learners participating since inception. Facilitated 36 clinical research trials inclusive of many leading psychedelic drug development companies. Since Numinus was founded, there have been significant advancements in psychedelic therapy, and we take pride in our substantial contributions to this sector that positively impact people's lives. The results of our efforts can be seen in the increasing number of client visits, our research collaborations with leading drug developers and the growth of our training platform for practitioners. The anticipated approval of MDMA-assisted therapy by the FDA, if approved, will provide us with increased opportunities to deploy our unique service model using another treatment modality. We are migrating our courses to a new Learning Management System, enhancing our training program by significantly improving learner engagement, satisfaction, ease of navigation and overall community experience. Additionally, our new free Introduction to Psychedelics course will be launched in the next two weeks to help broaden the awareness of the benefits of PAT while also providing greater brand awareness and lead generation for the full program.

Numinus wellness inc

In connection with the Offering, Numinus has secured a lead order from Integrated V. For more than half a century, therapists have expressed a desire to have the opportunity for their own psychedelic experiences as part of their training to feel better prepared to use these medicines to treat their patients. Given the potential demand for novel psychedelic-assisted therapy treatments, there will be a critical need for trained professionals to administer care. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Smartcrib

Learn More Watch Video. Leave a Reply Cancel Reply Your email address will not be published. Use our equities screener to discover other potential opportunities. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Add to Your Watchlists New watchlist. Braxia Scientific cash dwindles even as revenues rise. We offer premium psychedelic-assisted therapy training for licensed and non-licensed providers. Training with Numinus Learn from the experts. Looking to become a certified psychedelic Therapist? Post Comment.

Each Unit consists of one common share in the capital of Numinus each, a " Common Share " and one Common Share purchase warrant of Numinus each, a " Warrant ". As the new drug application for MDMA was recently accepted by the United States Food and Drug Administration, our clinical research team is continuing to work with exciting new drugs and treatments and our training platform is helping to address the critical need for practitioners to provide psychedelic-assisted therapy," said Payton Nyquvest , Numinus' Founder and CEO.

Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. The financing drew support from a cohort that includes MAPS. According to the Numinus, the proceeds from the offering are intended for working capital and general corporate purposes. Our holistic, integrated approach to healing, combines the latest advances in medicine with the best in evidence-based care. Get support on your path to wellness. Toronto Client. All markets data located on FT. Add to Your Portfolio New portfolio. Show more US link US. Search Search for:. Show more Opinion link Opinion.